Philanthropic Funding Provided by:
| Tx name | MPP-021 |
| Description | A clinically validated cognitive enhancer with newly discovered anticonvulsant, neuroprotective and analgesic effects is in development as the multifunctional mechanism-based CNS drug candidate for the treatment of neurological and neurodegenerative diseases and disorders. Novel analogs of MPP-021 have improved profile as potential AEDs and adjuvant analgesics, particularly for the treatment of neuropathic pain. |
| Company | MediProPharma |
| Status | |
| Overview | Challenges: Selection of at least two therapeutic indications for clinical development of MPP-021 to maximize the drug developmental potential. Identification of the IND candidate as a novel AED and adjuvant analgesic from novel analogs of MPP-021 via comprehensive in vivo profiling of at least two candidate compounds. |
| PK | |
| indications | |
| preclin data | |
| preclin tox | |
| Phase 1 | |
| Phase 2 | |
| Phase 3 | |
| Adverse effects | |
| publications | |
| IP | |
| Potential problems | |
| Timeline | |
| Financial Status | |
| Partnerships | Need Early-stage partnering with big pharma or Series B investment in mid-2010. |
| ETP Support |